



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Aminoxy-PEG3-azide

<b>Cat. No.:</b>	HY-126949
<b>CAS No.:</b>	1306615-51-9
<b>Molecular Formula:</b>	C <sub>8</sub> H <sub>18</sub> N <sub>4</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	234.25
<b>Target:</b>	ADC Linker; PROTAC Linkers
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Aminoxy-PEG3-azide is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)<sup>[1]</sup>. Aminoxy-C2-PEG3-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs<sup>[2]</sup>. Aminoxy-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.</p>	
<b>IC<sub>50</sub> &amp; Target</b>	PEGs	Non-cleavable Linker
<b>In Vitro</b>	<p>ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker<sup>[1]</sup>. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

### REFERENCES

- [1]. Chanhyuk KIM, et al. Optimized chimeric receptor t cell switches and uses thereof. WO2016168766A1.
- [2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA